Health
NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali – – pharmaphorum
NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for previously treated breast cancer patients….
NICE has recommended moving Novartis Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients.
In the final draft guidance, NICE recommended Kiskali be taken out of the Cancer Drugs Fund, which has been providing interim reimbursement since 2019 until further trial data emerged addressing uncertainties about overall survival and cost-effectiveness.
These data are now available from the phase 3 MONALEESA-3, a randomised…
-
General21 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
Noosa News24 hours agoSanta drops in for carols
-
General14 hours agoAshes engulfed by fresh DRS controversy as TV umpire gives Jamie Smith out despite RTS ‘murmur’
-
General22 hours agoTwo dead after separate road accidents in regional New South Wales